Prospective, Multicenter Study of the MTOR inhibitor Everolimus (RAD001) as Primary Therapy in Waldenstrom’s Macroglobulinemia.

Treon SP, Tripsas CK, Ioakimidis L, Warren D, Patterson CJ, Hefner LT, Eradat H, Gregory S, Thomas S, Advani R, Baz R, Badros A, Matous J, Anderson KC, Ghobrial IM. Dana Farber Cancer Institute, Boston MA, USA; Winship Cancer Institute, Emory University, Atlanta GA, USA; University of California, Los Angeles Medical Center, Los Angeles CA, USA; Rush University Medical Center, Chicago IL, USA; MD Anderson Cancer Center, Houston TX, USA; Stanford University Medical Center, Palo Alto CA, USA; H. Lee Moffitt Cancer Center, Tampa, FL, USA; University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA; Rocky Mountain Cancer Center, Denver CO, USA.

INTRODUCTION

Everolimus (RAD001) is an inhibitor of MTORC1, a component of the Akt–MTOR pathway which regulates growth and survival of lymphoplasmacytic cells in Waldenstrom’s Macroglobulinemia (WM). Everolimus also exhibits activity in WM patients with relapsed/refractory disease (Ghobrial et al, JCO 2010; 28:1408-14). We therefore initiated this multicenter, prospective study to delineate the efficacy and tolerability of Everolimus as primary therapy in WM.

PATIENTS AND METHODS

WM patients with symptomatic disease, adequate organ function, who were not previously treated, and who did not have symptomatic hyperviscosity were eligible for this study. Intended therapy consisted of 10 mg of oral Everolimus administered daily, with sequential dose de-escalation to 7.5 mg daily, 5 mg daily, and 5 mg every other day permitted for toxicity. Patients were treated until progression or unacceptable toxicity. Patients were encouraged to use 5 mL of oral dexamethasone solution (0.5 mg/5mL) to swish and spit up to 4 times daily for prevention of oral ulcerations associated with Everolimus. Study patients were assessed monthly for the first 3 months, and thereafter every 3 months which included a physical examination, complete blood counts, chemistries, and serum IgM monitoring. Bone marrow biopsies and aspirations were performed at baseline, at months 6 and 12, and as required for response assessment.

Baseline and Post-Everolimus Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Baseline Median (range)</th>
<th>Post-Everolimus Median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>62 years (37-83 years)</td>
<td>64 years (42-82 years)</td>
</tr>
<tr>
<td>Hematocrit*</td>
<td>37.3% (24.9-47.8%)</td>
<td>30.6% (20.2-36.8%)</td>
</tr>
<tr>
<td>Hemoglobin*</td>
<td>10.4 g/dL (7.8-15.7 g/dL)</td>
<td>10.4 g/dL (8.6-14.1 g/dL)</td>
</tr>
<tr>
<td>Serum IgM**</td>
<td>4.44 mg/dL (2.85-10.26 mg/dL)</td>
<td>2.84 mg/dL (1.16-7.20 mg/dL)</td>
</tr>
<tr>
<td>WBC (K/mm^3)</td>
<td>2.60 g/dL (2.13-5.31 g/dL)</td>
<td>3.50 g/dL (2.22-4.31 g/dL)</td>
</tr>
</tbody>
</table>

Bone marrow involvement (interstitial disease) 76% (7.5-95%) 65% (10-85%)

*p value not statistically significant

CONCLUSIONS

- Everolimus is associated with rapid reductions observed in serum IgM levels in WM patients.
- Serum IgM discordance to underlying bone marrow disease burden is common, and serial bone marrow assessments are important for response monitoring in WM patients receiving Everolimus.
- With a median follow-up of 9 months (range 0-18 months), 15 patients remain on study.
- Reasons for study discontinuation included nonresponse or disease progression (n=11), unacceptable toxicity (n=6, including 5 for pneumonitis and 1 for neutropenia), and loss of follow-up (n=1).

Serum IgM Levels for All Participants (n=33)

Bone Marrow Response vs. Serum IgM Response for Patients who Completed Cycle 6 (n=26)

Frequency of all Possibly Related Adverse Events, All Grades

Grade 2 hematologic and non-hematologic toxicities possibly, probably or definitively associated with Everolimus.

- Everolimus is associated with rapid reductions observed in serum IgM levels in WM patients.
- Serum IgM discordance to underlying bone marrow disease burden is common, and serial bone marrow assessments are important for response monitoring in WM patients receiving Everolimus.
- With a median follow-up of 9 months (range 0-18 months), 15 patients remain on study.
- Reasons for study discontinuation included nonresponse or disease progression (n=11), unacceptable toxicity (n=6, including 5 for pneumonitis and 1 for neutropenia), and loss of follow-up (n=1).